Avacta Group’s (AVCT) Corporate Rating Reaffirmed at FinnCap

Avacta Group (LON:AVCT)‘s stock had its “corporate” rating reissued by investment analysts at FinnCap in a research report issued on Monday, February 4th.

LON AVCT traded up GBX 0.50 ($0.01) during trading on Monday, hitting GBX 41.30 ($0.54). 171,938 shares of the company’s stock traded hands, compared to its average volume of 19,964. Avacta Group has a 12-month low of GBX 40 ($0.52) and a 12-month high of GBX 98 ($1.28).

In other Avacta Group news, insider Tony Peter Gardiner purchased 8,196 shares of the business’s stock in a transaction on Monday, December 31st. The stock was acquired at an average cost of GBX 31 ($0.41) per share, for a total transaction of £2,540.76 ($3,319.95).

About Avacta Group

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.